Q2 Earnings Forecast for OPKO Health Issued By HC Wainwright

OPKO Health, Inc. (NASDAQ:OPK) – Stock analysts at HC Wainwright lowered their Q2 2025 earnings per share estimates for shares of OPKO Health in a report released on Monday, March 3rd. HC Wainwright analyst Y. Chen now anticipates that the biotechnology company will earn ($0.08) per share for the quarter, down from their previous forecast of ($0.07). HC Wainwright has a “Buy” rating and a $3.00 price objective on the stock. The consensus estimate for OPKO Health’s current full-year earnings is ($0.25) per share. HC Wainwright also issued estimates for OPKO Health’s Q3 2025 earnings at ($0.08) EPS, Q4 2025 earnings at ($0.07) EPS and FY2025 earnings at ($0.31) EPS.

OPKO Health (NASDAQ:OPK) last issued its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.01 EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.09. The business had revenue of $183.60 million for the quarter, compared to analyst estimates of $155.42 million. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%.

Other analysts also recently issued research reports about the company. Barrington Research reiterated an “outperform” rating and issued a $2.25 price objective on shares of OPKO Health in a research report on Friday, February 28th. StockNews.com upgraded OPKO Health from a “sell” rating to a “hold” rating in a research report on Monday.

OPKO Health Stock Performance

OPK opened at $1.94 on Thursday. The firm has a market capitalization of $1.32 billion, a P/E ratio of -10.21 and a beta of 1.63. The stock’s 50 day moving average price is $1.56 and its two-hundred day moving average price is $1.55. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30. OPKO Health has a 12-month low of $0.86 and a 12-month high of $2.04.

Insiders Place Their Bets

In other news, CEO Phillip Md Et Al Frost acquired 47,537 shares of OPKO Health stock in a transaction on Tuesday, January 28th. The stock was bought at an average price of $1.47 per share, for a total transaction of $69,879.39. Following the transaction, the chief executive officer now owns 213,234,014 shares of the company’s stock, valued at $313,454,000.58. The trade was a 0.02 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. In the last quarter, insiders bought 1,389,971 shares of company stock worth $2,124,442. 47.26% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On OPKO Health

Several hedge funds and other institutional investors have recently modified their holdings of OPK. FMR LLC lifted its position in shares of OPKO Health by 103.6% during the 3rd quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock worth $32,000 after buying an additional 11,089 shares during the period. Orion Portfolio Solutions LLC bought a new position in shares of OPKO Health during the 3rd quarter worth approximately $45,000. Cibc World Markets Corp bought a new position in shares of OPKO Health during the 4th quarter worth approximately $45,000. Zacks Investment Management bought a new position in shares of OPKO Health during the 4th quarter worth approximately $49,000. Finally, Ieq Capital LLC bought a new position in shares of OPKO Health during the 4th quarter worth approximately $52,000. Institutional investors own 64.63% of the company’s stock.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.